FindTrial
Sign In

Placebo to Ertugliflozin

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Diabetes Mellitus, Type 2Healthy VolunteerType 2 Diabetes Mellitus

Phase 1

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
CompletedNCT00989079
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2009-10-16End: 2009-12-11Updated: 2020-05-29
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
CompletedNCT01018823
Merck Sharp & Dohme LLCHealthy Volunteer
Start: 2009-12-14End: 2010-03-18Updated: 2020-05-29

Phase 2

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
CompletedNCT01059825
Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2
Start: 2010-02-24End: 2011-01-20Updated: 2018-09-13

Phase 3

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
CompletedNCT01958671
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-10-09End: 2016-07-28Updated: 2017-09-29
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
CompletedNCT01999218
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-12-16End: 2017-04-18Updated: 2019-04-02
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
CompletedNCT02033889
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-12-13End: 2017-08-03Updated: 2018-09-10
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
CompletedNCT02226003
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2014-09-23End: 2016-02-23Updated: 2018-09-13

Related Papers

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Diabetes Therapy2023-02-012 citations
Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
CPT Pharmacometrics & Systems Pharmacology2020-12-1218 citations
The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies
Diabetes Obesity and Metabolism2020-07-236 citations
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Diabetes Therapy2020-07-0914 citations
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
2020-05-0518 citations
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-2310 citations
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-233 citations
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
Diabetologia2020-03-3140 citations
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
2020-01-039 citations
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Diabetes and Vascular Disease Research2019-05-1325 citations
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
Cardiovascular Diabetology2019-05-0720 citations
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Current Medical Research and Opinion2019-02-1450 citations
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
Diabetes Obesity and Metabolism2019-01-0863 citations
A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin
Diabetes2018-06-223 citations
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
2018-02-2363 citations
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Diabetes Therapy2018-01-0882 citations
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Diabetes Therapy2017-12-27106 citations
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
2017-10-02137 citations